Live Salesforce, Inc. Vote →

Never Miss Important Company Updates Again

Get AI-powered summaries of SEC filings delivered to your inbox

Follow your favorite stocks and get email alerts when they release important updates. Completely free.

Covers 5,000+ public companies
Get started →
Sign up to stay up to date with the stocks you care about
Follow Sensei Biotherapeutics, Inc.

Get SEC filing alerts via email and in your feed for Sensei Biotherapeutics, Inc.

SNSE

Sensei Biotherapeutics, Inc.

About Sensei Biotherapeutics, Inc.

Sensei Biotherapeutics is a clinical-stage biotech focused on developing next-generation cancer immunotherapies. Using its TMAb platform, it creates highly selective biologics that modulate the tumor microenvironment by targeting immune checkpoints like VISTA. Its products aim to enhance anti-tumor immune responses, often in combination with existing therapies, serving patients with various solid tumors through innovative, tumor-specific mechanisms.
This description was generated via AI from an annual report. Updated 8 months ago.

Latest SEC Filings from Sensei Biotherapeutics, Inc.

1
1
Sensei Biotherapeutics, Inc. Sensei Biotherapeutics Reports $170.2 Million Net Loss Following Faeth Therapeutics Acquisition

Via official filing (AI summary) | 20 days ago | 0 comments

2
1
Sensei Biotherapeutics, Inc. Sensei Biotherapeutics Completes Acquisition of Faeth Therapeutics and Reports Fiscal Year 2025 Results

Via official filing (AI summary) | 2 months ago | 0 comments

3
1
Sensei Biotherapeutics, Inc. Sensei Biotherapeutics Reports $16.4 Million Net Loss, Announces Workforce Reduction and Strategic Review

Via official filing (AI summary) | 7 months ago | 0 comments

4
1
Sensei Biotherapeutics, Inc. Sensei Biotherapeutics Reports $11.8 Million Net Loss for First Half of 2025

Via official filing (AI summary) | 10 months ago | 0 comments

5
1
Sensei Biotherapeutics, Inc. Sensei Biotherapeutics Reports $6.9 Million Net Loss in Q1 2025, Faces Liquidity Concerns

Via official filing (AI summary) | about 1 year ago | 0 comments

6
1
Sensei Biotherapeutics, Inc. Sensei Biotherapeutics Reports $30.2M Net Loss for 2024, Advances Solnerstotug Clinical Trial

Via official filing (AI summary) | about 1 year ago | 0 comments

7
1
Sensei Biotherapeutics, Inc. Sensei Biotherapeutics Reports Q3 Financial Results, Announces Restructuring Plan

Via official filing (AI summary) | over 1 year ago | 0 comments